|Bid||0.00 x 1000|
|Ask||50.23 x 800|
|Day's Range||46.92 - 49.07|
|52 Week Range||15.25 - 52.10|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.56|
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, has submitted a premarket approval (PMA) supplement to the FDA for the purpose of gaining detachable extremity coil magnetic resonance imaging (MRI) conditional labeling for 1.5T and 3.0T MR scanners.
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The Dow Jones rose in today's market but pared earlier gains to a much smaller gain by the close. The Tuesday coronavirus stimulus deadline draws closer.